Tyrosine kinase inhibitors induced thyroid dysfunction: A review of its incidence, pathophysiology, clinical relevance, and treatment

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Ahmadieh, Hala ^a   Salti, Ibrahim ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; DASATINIB; IMATINIB; LEVOTHYROXINE; MOTESANIB; NILOTINIB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; THYROTROPIN; TIVOZANIB; VANDETANIB; PROTEIN KINASE INHIBITOR;

FOLLOW UP; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LYMPHOCYTIC THYROIDITIS; PATHOPHYSIOLOGY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROGRESSION FREE SURVIVAL; REVIEW; SUBCLINICAL HYPOTHYROIDISM; THYROID DISEASE; THYROID FUNCTION; THYROID FUNCTION TEST; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; ANIMAL; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; PATHOLOGY; THYROID GLAND;

ANIMALS; CARCINOMA, RENAL CELL; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; THYROID GLAND; THYROIDITIS;

EID: 84888636136     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/725410     Document Type: Review

References (60)

1. Le Tourneau C., Faivre S., Raymond E., New developments in multitargeted therapy for patients with solid tumours. Cancer Treatment Reviews 2008 34 1 37 48 2-s2.0-38649129787 10.1016/j.ctrv.2007.09.003 (Pubitemid 351168610)
2. Arora A., Scholar E. M., Role of tyrosine kinase inhibitors in cancer therapy. The Journal of Pharmacology and Experimental Therapeutics 2005 315 3 971 979 2-s2.0-27544479318 10.1124/jpet.105.084145 (Pubitemid 41635382)
3. Cilloni D., Messa E., Messa F., Carturan S., Defilippi I., Arruga F., Rosso V., Catalano R., Bracco E., Nicoli P., Saglio G., Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes. Annals of the New York Academy of Sciences 2006 1089 411 423 2-s2.0-33847790838 10.1196/annals.1386.030 (Pubitemid 47092085)
4. Paul M., Mukhopadhyay A., Tyrosine kinase-role and significance in cancer. International Journal of Medical Sciences 2004 1 2 101 115 10.7150/ijms.1.101
5. Izzedine H., Buhaescu I., Rixe O., Deray G., Sunitinib malate. Cancer Chemotherapy and Pharmacology 2007 60 3 357 364 2-s2.0-34250664685 10.1007/s00280-006-0376-5 (Pubitemid 46944582)
6. Ezzeldin M., Ghieth A., Khaled M., Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis. International Journal of Clinical Oncology 2012 10.1007/s10147-012-0497-2
7. Wilhelm S. M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L. E., Bollag G., Trail P. A., BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 2004 64 19 7099 7109 2-s2.0-4944249117 10.1158/0008-5472.CAN-04-1443 (Pubitemid 39331023)
8. Mendel D. B., Douglas Laird A., Xin X., Louie S. G., Christensen J. G., Li G., Schreck R. E., Abrams T. J., Ngai T. J., Lee L. B., Murray L. J., Carver J., Chan E., Moss K. G., Haznedar J. Ö., Sukbuntherng J., Blake R. A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J. M., In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research 2003 9 1 327 337 2-s2.0-12244301581 (Pubitemid 36109749)
9. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R. A., Schwartz B., Simantov R., Kelley S., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery 2006 5 10 835 844 2-s2.0-33749238553 10.1038/nrd2130 (Pubitemid 44480537)
10. Motzer R. J., Hutson T. E., Tomczak P., Michaelson D., Bukowski R. M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S. T., Chen I., Bycott P. W., Baum C. M., Figlin R. A., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England Journal of Medicine 2007 356 2 115 124 2-s2.0-33846181370 10.1056/NEJMoa065044 (Pubitemid 46089672)
11. Escudier B., Eisen T., Stadler W. M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A. A., Rolland F., Demkow T., Hutson T. E., Gore M., Freeman S., Schwartz B., Shan M., Simantov R., Bukowski R. M., Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine 2007 356 2 125 134 2-s2.0-33846148701 10.1056/NEJMoa060655 (Pubitemid 46089673)
12. Demetri G. D., van Oosterom A. T., Garrett C. R., Blackstein M. E., Shah M. H., Verweij J., McArthur G., Judson I. R., Heinrich M. C., Morgan J. A., Desai J., Fletcher C. D., George S., Bello C. L., Huang X., Baum C. M., Casali P. G., Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. The Lancet 2006 368 9544 1329 1338 2-s2.0-33749505836 10.1016/S0140-6736(06)69446-4 (Pubitemid 44528723)
13. Abou-Alfa G. K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., de Greve J., Douillard J.-Y., Lathia C., Schwartz B., Taylor I., Moscovici M., Saltz L. B., Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology 2006 24 26 4293 4300 2-s2.0-33749017926 10.1200/JCO.2005.01.3441 (Pubitemid 46630787)
14. Desai J., Yassa L., Marqusee E., George S., Frates M. C., Chen M. H., Morgan J. A., Dychter S. S., Larsen P. R., Demetri G. D., Alexander E. K., Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Annals of Internal Medicine 2006 145 9 660 664 2-s2.0-33750961647 (Pubitemid 46768841)
15. Rini B. I., Tamaskar I., Shaheen P., Salas R., Garcia J., Wood L., Reddy S., Dreicer R., Bukowski R. M., Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. Journal of the National Cancer Institute 2007 99 1 81 83 2-s2.0-33846978108 10.1093/jnci/djk008
16. Wong E., Rosen L. S., Mulay M., VanVugt A., Dinolfo M., Tomoda C., Sugawara M., Hershman J. M., Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007 17 4 351 355 2-s2.0-34248632840 10.1089/thy.2006.0308 (Pubitemid 46776140)
17. Mannavola D., Coco P., Vannucchi G., Bertuelli R., Carletto M., Casali P. G., Beck-Peccoz P., Fugazzola L., A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. Journal of Clinical Endocrinology and Metabolism 2007 92 9 3531 3534 2-s2.0-34548764576 10.1210/jc.2007-0586 (Pubitemid 47435331)
18. Wolter P., Stefan C., Decallonne B., Dumez H., Bex M., Carmeliet P., Schöffski P., The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. British Journal of Cancer 2008 99 3 448 454 2-s2.0-48349122489 10.1038/sj.bjc.6604497
19. Shinohara N., Takahashi M., Kamishima T., Ikushima H., Otsuka N., Ishizu A., Shimizu C., Kanayama H., Nonomura K., The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. British Journal of Cancer 2011 104 2 241 247 2-s2.0-78751579135 10.1038/sj.bjc.6606029
20. Funakoshi T., Shimada Y., Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis. Acta Oncologica 2012 52 4 691 702 10.3109/0284186X.2012.752579
21. Tamaskar I., Bukowski R., Elson P., Ioachimescu A. G., Wood L., Dreicer R., Mekhail T., Garcia J., Rini B. I., Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Annals of Oncology 2008 19 2 265 268 2-s2.0-38849093794 10.1093/annonc/mdm483 (Pubitemid 351201706)
22. Clement P., Stefan C., Decallonne P., Dumez H., Wildiers H., Schöffski P., Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib. Journal of Clinical Oncology 2008 26 15 supplement, abstract 16145
23. Schmidinger M., Vogl U., Bojic M., Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 2011 117 3 534 544 10.1002/cncr.25422
24. Riesenbeck L. M., Bierer S., Hoffmeister I., Köpke T., Papavassilis P., Hertle L., Thielen B., Herrmann E., Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World Journal of Urology 2011 29 6 807 813 2-s2.0-81855163405 10.1007/s00345-010-0627-2
25. de Groot J. W. B., Zonnenberg B. A., van Ufford-Mannesse P. Q., de Vries M. M., Links T. P., Lips C. J. M., Voest E. E., A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 9 3466 3469 2-s2.0-34548749440 10.1210/jc.2007-0649 (Pubitemid 47435321)
26. de Groot J. W. B., Zonnenberg B. A., Plukker J. T. M., van der Graaf W. T. A., Links T. P., Imatinib induces hypothyroidism in patients receiving levothyroxine. Clinical Pharmacology and Therapeutics 2005 78 4 433 438 2-s2.0-25844471013 10.1016/j.clpt.2005.06.010 (Pubitemid 41393678)
27. Kim T. D., Schwarz M., Nogai H., Grille P., Westermann J., Plöckinger U., Braun D., Schweizer U., Arnold R., Dörken B., Le Coutre P., Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 2010 20 11 1209 1214 2-s2.0-78249244171 10.1089/thy.2010.0251
28. Ohba K., Takayama T., Matsunaga H., Matsushita A., Sasaki S., Oki Y., Ozono S., Nakamura H., Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid 2013 23 4 443 448 10.1089/thy.2012.0378
29. Fujiwara Y., Kiyota N., Chayahara N., Suzuki A., Umeyama Y., Mukohara T., Minami H., Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Investigational New Drugs 2012 30 3 1055 1064 2-s2.0-79551599346 10.1007/s10637-011-9637-1
30. Mukohara T., Nakajima H., Mukai H., Nagai S., Itoh K., Umeyama Y., Hashimoto J., Minami H., Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Science 2010 101 4 963 968 2-s2.0-77957269382 10.1111/j.1349-7006.2009.01465.x
31. Rini B. I., Escudier B., Tomczak P., Kaprin A., Szczylik C., Hutson T. E., Michaelson M. D., Gorbunova V. A., Gore M. E., Rusakov I. G., Negrier S., Ou Y.-C., Castellano D., Lim H. Y., Uemura H., Tarazi J., Cella D., Chen C., Rosbrook B., Kim S., Motzer R. J., Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. The Lancet 2011 378 9807 1931 1939 2-s2.0-82755183572 10.1016/S0140-6736(11) 61613-9
32. Wolter P., McCann L., Sternberg C. N., Hutson T. E., Mehmud F., Pandite L. N., Schoffski P., Incidence of thyroid dysfunction in renal cell carcinoma (RCC) patients treated with pazopanib in prospective clinical trials. Journal of Clinical Oncology 2011 29, abstract 4633
33. Sternberg C. N., Davis I. D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C. H., Salman P., Gladkov O. A., Kavina A., Zarbá J. J., Chen M., McCann L., Pandite L., Roychowdhury D. F., Hawkins R. E., Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology 2010 28 6 1061 1068 2-s2.0-77949890945 10.1200/JCO.2009.23.9764
34. Motzer R. J.,. A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects with Advanced Renal Cell Carcinoma (TIVO-1) ongoing trial
35. Sherman S. I., Wirth L., Droz J., Hofmann M., Bastholt L., Martins R. G., Licitra L., Eschenberg M. J., Sun Y.-N., Juan T., Stepan D. E., Schlumberger M. J., Motesanib diphosphate in progressive differentiated thyroid cancer. The New England Journal of Medicine 2008 359 1 31 42 2-s2.0-46449117698 10.1056/NEJMoa075853 (Pubitemid 351931094)
36. Robinson B. G., Paz-Ares L., Krebs A., Vasselli J., Haddad R., Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2010 95 6 2664 2671 2-s2.0-77954478933 10.1210/jc.2009-2461
37. Sakurai K., Fukazawa H., Arihara Z., Yoshida K., Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. The Tohoku Journal of Experimental Medicine 2010 222 1 39 44 2-s2.0-79955061037
38. Faris J. E., Moore A. F., Daniels G. H., Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 2007 17 11 1147 1149 2-s2.0-36749072043 10.1089/thy.2007.0104 (Pubitemid 350207759)
39. van Doorn L., Eskens F. A. L. M., Visser T. J., van der Lugt A., Mathijssen R. H. J., Peeters R. P., Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid 2011 21 2 197 202 2-s2.0-79953251489 10.1089/thy.2010.0234
40. Degertekin C., Coşkun U., Törüner F., Aktürk M., Demirci U., Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer. Endocrine 2012 42 3 756 757 10.1007/s12020-012- 9683-2
41. Makita N., Iiri T., Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid 2013 23 2 151 159 10.1089/thy.2012.0456
42. Grossmann M., Premaratne E., Desai J., Davis I. D., Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clinical Endocrinology 2008 69 4 669 672 2-s2.0-51649122915 10.1111/j.1365-2265.2008.03253.x
43. Kamba T., Tam B. Y. Y., Hashizume H., Haskell A., Sennino B., Mancuso M. R., Norberg S. M., O'Brien S. M., Davis R. B., Gowen L. C., Anderson K. D., Thurston G., Joho S., Springer M. L., Kuo C. J., McDonald D. M., VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. American Journal of Physiology 2006 290 2 H560 H576 2-s2.0-32944474182 10.1152/ajpheart.00133.2005
44. Baffert F., Le T., Sennino B., Thurston G., Kuo C. J., Hu-Lowe D., McDonald D. M., Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. American Journal of Physiology 2006 290 2 H547 H559 2-s2.0-32944466693 10.1152/ajpheart.00616.2005
45. Yamada E., Yamazaki K., Takano K., Obara T., Sato K., Iodide inhibits vascular endothelial growth factor-A expression in cultured human thyroid follicles: a microarray search for effects of thyrotropin and iodide on angiogenesis factors. Thyroid 2006 16 6 545 554 2-s2.0-33745982267 10.1089/thy.2006.16.545 (Pubitemid 44066261)
46. Jebreel A., England J., Bedford K., Murphy J., Karsai L., Atkin S., Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. International Journal of Experimental Pathology 2007 88 4 271 277 2-s2.0-34547865714 10.1111/j.1365-2613.2007.00533.x (Pubitemid 47256303)
47. Hoffmann S., Hofbauer L. C., Scharrenbach V., Wunderlich A., Hassan I., Lingelbach S., Zielke A., Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. Journal of Clinical Endocrinology and Metabolism 2004 89 12 6139 6145 2-s2.0-10344258027 10.1210/jc.2004-1260 (Pubitemid 39628426)
48. Salem A. K., Fenton M. S., Marion K. M., Hershman J. M., Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 2008 18 6 631 635 2-s2.0-46349101365 10.1089/thy.2007.0336 (Pubitemid 351918450)
49. Ferrara N., Hillan K. J., Gerber H. P., Novotny W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery 2004 3 5 391 400 2-s2.0-2442621619 (Pubitemid 38618122)
50. van Cruijsen H., van der Veldt A., Hoekman K., Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. Frontiers in Bioscience 2009 14 6 2248 2268 2-s2.0-62449192134 10.2741/3377
51. van der Veldt A. A. M., de Boer M. P., Boven E., Eringa E. C., van den Eertwegh A. J. M., van Hinsbergh V. W., Smulders Y. M., Serné E. H., Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anti-Cancer Drugs 2010 21 4 439 446 2-s2.0-77949400086 10.1097/CAD.0b013e3283359c79
52. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., de Mol M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., Dipalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., Vandendriessche T., Ponten A., Eriksson U., Plate K. H., Foidart J.-M., Schaper W., Charnock-Jones D. S., Hicklin D. J., Herbert J.-M., Collen D., Persico M. G., Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Medicine 2001 7 5 575 583 2-s2.0-19244379078 10.1038/87904 (Pubitemid 32448325)
53. van der Veldt A., Lammertsma A., Smit E., Reduction in thyroid perfusion after bevacizumab treatment. Thyroid 2013 23 10.1089/thy.2013.0147
54. Wolter P., Decallonne B., Dumez H., Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). Journal of Clinical Oncology 2008 26 15 supplement, abstract 5126
55. Rivas M., Santisteban P., TSH-activated signaling pathways in thyroid tumorigenesis. Molecular and Cellular Endocrinology 2003 213 1 31 45 2-s2.0-1242318752 10.1016/j.mce.2003.10.029 (Pubitemid 38229153)
56. Shinohara N., Kamishima T., Ikushima H., Efficacy and thyroidal effects of sunitinib in Japanese patients with metastatic renal cell carcinoma: hypothyroidism and thyroid atrophy as potential biomarkers for sunitinib? Journal of Clinical Oncology 2009 27 supplement, abstract e16097
57. Illouz F., Laboureau-Soares S., Dubois S., Rohmer V., Rodien P., Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. European Journal of Endocrinology 2009 160 3 331 336 2-s2.0-62649174250 10.1530/EJE-08-0648
58. Brown R. L., Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management. Targeted Oncology 2011 6 4 217 226 2-s2.0-84856071108 10.1007/s11523-011-0197-2
59. Garfield D., Hercbergs A., Davis P., Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nature Clinical Practice Oncology 2007 4 12 674 675 2-s2.0-36549031784 10.1038/ncponc0998 (Pubitemid 350186998)
60. Bladou F., Sabatier R., Deville J., Hypothyroidism and survival during sunitinib therapy in metastatic renal cell carcinoma (mRCC): a prospective observational analysis. Journal of Clinical Oncology 28 supplement, abstract e15013